ThermoGenesis has leased a facility in Sacramento, California to house its newly launched CDMO cell therapy business TG Biosynthesis.¬†
ThermoGenesis (formerly known as Cesca Therapeutics), which provides cell processing tools and services to the cell and gene therapy sector, is bolstering its offering by creating a cell therapy production division.¬†¬†
The firm will deliver contract development manufacturing organization (CDMO) services under the name TG Biosynthesis. To create this, ThermoGenesis entered into a license and technology agreement with Boyalife Genomics, a China-based CDMO.
‚ÄúCell therapies have become the ‚Äėnext pillar‚Äô of medicine, and we plan to leverage our [‚Ä¶] automated and semi-automated cell processing technologies, including the CAR-TXpress platform, to expand from a device company to one focused on providing world-class CDMO services,‚ÄĚ said Chris Xu, CEO at ThermoGenesis.¬†¬†
‚ÄúWe are eager to begin this process, with the intent that our new, TG Biosynthesis division will combine our existing in-house expertise and technology with that obtained through our license agreement, to develop a proprietary cell manufacturing platform ‚Äď providing valuable solutions for clients with therapeutic candidates in various stages of development.‚ÄĚ¬†
Under terms of the agreement with Boyalife, ThermoGenesis will be provided with a US license ‚Äúto certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes.‚ÄĚ¬†
Boyalife will receive a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of its granted US patents as well as a royalty of 5% of other products and services covered by further licensed intellectual property.¬†¬†
Space in Sacramento¬†¬†
ThermoGenesis has also entered into a lease agreement with Z3 Investment, effective from April 1, 2022, for around 35,475 square feet of laboratory and office space in Sacramento, California.¬†¬†
The firm claims the site will create approximately 100 jobs in the area and will be built-out to be a current good manufacturing practice (cGMP) compliant plant with 12 clean room suites.